0001140361-17-037828.txt : 20171006 0001140361-17-037828.hdr.sgml : 20171006 20171006183734 ACCESSION NUMBER: 0001140361-17-037828 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171004 FILED AS OF DATE: 20171006 DATE AS OF CHANGE: 20171006 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McCarthy Sean A. CENTRAL INDEX KEY: 0001654058 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37587 FILM NUMBER: 171128329 MAIL ADDRESS: STREET 1: 343 OYSTER POINT BLVD. STREET 2: SUITE 100 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CytomX Therapeutics, Inc. CENTRAL INDEX KEY: 0001501989 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 273521219 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 151 OYSTER POINT BLVD. STREET 2: SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650.515.3185 MAIL ADDRESS: STREET 1: 151 OYSTER POINT BLVD. STREET 2: SUITE 400 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc1.xml FORM 4 X0306 4 2017-10-04 0 0001501989 CytomX Therapeutics, Inc. CTMX 0001654058 McCarthy Sean A. 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 1 1 0 0 President and CEO Common Stock 2017-10-04 4 M 0 19120 0.945 A 23365 D Common Stock 2017-10-04 4 S 0 19120 24.13 D 4245 D Common Stock 158737 I See footnote Common Stock 0.945 2017-10-04 4 M 0 19120 0 D 2023-02-25 Common Stock 19120 133635 D The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $23.51 to $24.39, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Held in McCarthy Family Trust dated August 9, 2001, Sean A. McCarthy and Jeanette J. McCarthy, Trustees. 100% of the shares subject to the option are fully vested and exercisable. Previous Form 4s filed by the Reporting Person included an error in the number of securities beneficially owned by the Reporting Person in Table II, Box 9. The number of derivative securities beneficially owned as reported in Table II, Box 9 of this Form 4 has been adjusted to correct the previous errors and reflects the current number of derivative securities beneficially owned as of this filing date. /s/ Cynthia J. Ladd, as Attorney-in-Fact for Sean A. McCarthy 2017-10-06